Myopia drug breakthrough: Sydnexis’ SYD-101 approved in Europe, Ryjunea launch next

Following the company's June 5 press release announcing European approval of SYD-101, a story was published featuring a Q&A on how Santen's commercial launch of the drug in Europe affects the company. You can read the June 6 story by Pallavi Madhiraju, titled "Myopia Drug Breakthrough: Sydnexis' SYD-101 Approved in Europe, Ryjunea Launch Next," at Business-News-Today.com.

Shared by Tyler Stowater, board member of Sydnexis, Inc.